Amplifon (AMP) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
17 Jan, 2026Executive summary
Revenues reached €1,744.8 million in the first nine months of 2024, up 8% at constant FX and 6.1% at current rates, driven by strong organic and M&A growth, especially in Americas and APAC, despite a soft European market.
Achieved high single-digit revenue growth in Q3 and 9M 2024, outperforming the market despite a challenging comparison base and soft European demand.
Net profit as reported was €104.2 million, slightly above last year, while recurring net profit declined to €107.4 million due to higher depreciation, amortization, and financial expenses.
Strategic focus on transforming the U.S. network to direct retail, expanding to 400 stores, and accelerating M&A, especially in France, Germany, U.S., and China.
Investments in marketing and audiologist capacity in Europe, particularly France, to prepare for expected market normalization and growth in 2025.
Financial highlights
Q3 2024 revenues were €567.6 million, up 8% at constant FX and 6.8% at current rates; recurring EBITDA €115 million (20.3% margin), down 40bps YoY.
Nine-month revenues up 6.1% at current FX and 8% at constant FX to €1.75 billion; recurring EBITDA €412.2 million (23.6% margin), up 10bps YoY.
Q3 recurring net profit was €17.5 million (margin 3.1%), down from €23.5 million, reflecting higher depreciation, amortization, and financial expenses.
Free cash flow for 9M 2024 was €50.6 million, down from €68.8 million in 2023, impacted by higher lease liabilities, financial expenses, and working capital absorption.
Net financial debt increased to €1,068.3 million (leverage 1.78x), mainly due to acquisitions and shareholder returns.
Outlook and guidance
Expects high single-digit revenue growth for full year 2024 at constant FX, with M&A contributing at least 3%.
Recurring EBITDA margin for 2024 expected broadly in line with 2023, despite lower operating leverage and higher marketing investments.
Anticipates European market normalization in Q4 and continued US growth; expects to outpace reference market.
Medium-term outlook remains optimistic for sustainable growth in sales and profitability.
Anticipates double-digit market growth in France in 2025, with Q2 as the inflection point.
Latest events from Amplifon
- Record organic growth and margin gains in H1 2026, with GN Hearing acquisition advancing.AMP
H1 2026 - Q1 2026 saw 2.2% organic growth, record profitability, and improved leverage.AMP
Q1 2026 - A €2.3B deal forms a global audiology leader, targeting €60–80M synergies by 2029.AMP
M&A announcement - Revenue up 1.7% at constant FX; Fit4Growth drives margin gains amid market headwinds.AMP
Q4 2025 - Q3 organic growth improved, but margins fell; FY2025 targets modest revenue and margin gains.AMP
Q3 2025 - Margins fell as revenue growth slowed, prompting a new margin improvement program.AMP
Q2 2025 - Strong H1 2024 growth and profitability, with robust M&A and global network expansion.AMP
Q2 2024 - Q1 2025 delivered record EBITDA margin, 2.6% revenue growth, and guidance confirmation.AMP
Q1 2025 - 2024 revenue rose 7% to €2.41bn, with 2025 guidance for further growth and margin gains.AMP
Q4 2024